Results 71 to 80 of about 2,106 (148)

Effect of CYP2D6, 2C19, and 3A4 Phenoconversion in Drug-Related Deaths

Toxics
Molecular autopsy is a very important tool in forensic toxicology. However, many determinants, such as co-medication and physiological parameters, should be considered for optimal results. These determinants could cause phenoconversion (PC), a discrepancy between the real metabolic profile after phenoconversion and the phenotype determined by the ...
Sanaa M. Aly, Benjamin Hennart, Jean-Michel Gaulier, Delphine Allorge   +3 more
openaire   +4 more sources

Molecular Mechanisms Driving Chemokine-mediated Prostate Myofibroblast Phenoconversion. [PDF]

, 2015
Benign prostate hyperplasia (BPH), a proliferative condition of the prostate common in aging in men, and smooth muscle hypercontractility are associated with urinary voiding dysfunction (LUTD) manifest as Lower Urinary Tract Symptoms (LUTS).
Rodriguez-Nieves, Jose Antonio
core  

Understanding variation in metoprolol response: CYP2D6, drug interactions, and phenoconversion

Pharmacogenomics
Metoprolol, a β1-selective blocker, is widely used for treating cardiovascular and non-cardiovascular conditions. Its pharmacokinetics (PK) and pharmacodynamics (PD) vary significantly between individuals, in part due to CYP2D6 genetic polymorphisms.
Bayan Azizi, David E. Lanfear, Jasmine A. Luzum   +2 more
openaire   +2 more sources

Factors associated with phenoconversion of idiopathic rapid eye movement sleep behavior disorder: a prospective study

This study explores the effect of risk factors on the progression of idiopathic rapid eye movement (REM) sleep behavior disorder (iRBD) to α-synucleinopathies in a Chinese cohort.
Piu Chan, Yuan Yuan, Yue Hou, Yanning Cai, Wei Mao, Yajie Zang, Xiaonan Liu, Shuqin Zhan, Yuan Li, Hui Zhang   +9 more
core   +1 more source

CXCL12-mediated Myofibroblast Phenoconversion is CXCR4-Dependent.

, 2012
N1 cell were treated in serum-free media with 20 ng/ml TGF-β1 or with 100 pM CXCL12 in the absence or presence of 25 uM AMD3100, or vehicle for 48 hr, then co-immunostained for COL1 (PE-cy5-conjugated Ab, red), αSMA (fluorescein-conjugated Ab, green), or
Mehrnaz Gharaee-Kermani (118877), Sathish Kasina (118881), Dafydd Thomas (118889), Bethany B. Moore (118885), Rohit Mehra (118892), Jill A. Macoska (118895)   +5 more
core   +1 more source

An Illustrative Case of Phenoconversion due to Multi-Drug Interactions

, 2020
The study of pharmacogenetics aids in the identification of variable therapeutic responses, identification of adverse reactions to drugs, and supports development and discovery. While advances in pharmacogenetic testing have been significant in recent years, The U.S.
openaire   +2 more sources

Phenoconversion of CYP3A4, CYP2C19 and CYP2D6 in Pediatrics, Adolescents and Young Adults With Lymphoma: Rationale and Design of the PEGASUS Study

Phenoconversion is the discrepancy between genotype-predicted phenotype and clinical phenotype, due to nongenetic factors. In oncology patients, the impact of phenoconversion on drug selection, efficacy, toxicity, and treatment outcomes is unknown.
Moore, C, Conyers, R, Khatri, D, Spelman, T, Elliott, DA, Somogyi, AA, Gwee, A, Alexander, M, Halman, A, Dyas, R, Stenta, T, Kirkpatrick, C, Wang, S, Williams, E   +13 more
core   +2 more sources

"Phenoconversion in adult patients with b-thalassemia"

Patients with clinically significant forms of β-thalassemia have been historically classified as having a β-thalassemia major or β-thalassemia intermedia phenotype, with the first primarily referring to patients who present with severe anemia during early childhood and require lifelong transfusion therapy and the latter relating to patients who present
Musallam KM, Barella S, Origa R, Ferrero GBm Lisi R, Pasanisi A, Long F, Gianesin B, Pinto V, Sciortino R, Roberti D, De Franceschi L, Culcasi M, Forni G   +12 more
openaire   +1 more source

Pure Autonomic Failure and Central Synucleinopathy Risk. [PDF]

JAMA Neurol
Beach P, Freeman R.
europepmc   +1 more source

Associations of CYP2B6, CYP2C19, and CYP2D6 isoforms and phenoconversion with sertraline pharmacokinetics. [PDF]

PLoS One
Tapia-Alzuguren B, Canga-Espina C, Molero P, Aldaz A.   +3 more
europepmc   +1 more source